Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 8, 2008. The report announces a significant change in the company's directorate rather than providing financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement regarding personnel changes and does not contain financial statements.
Material Changes
The primary material change reported is the departure of Chris Viehbacher, Executive Director and President of North American Pharmaceuticals. He is standing down from the Board effective September 8, 2008, and will leave the company on December 1, 2008, to pursue another opportunity.
Management Commentary and Risks
CEO Andrew Witty thanked Mr. Viehbacher for his significant contributions, describing him as one of the most talented and respected executives in the industry. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the company's 2007 Annual Report on Form 20-F.
Investor Verification Points
- Confirm the exact effective date of Chris Viehbacher's departure from the Board (September 8, 2008) versus his final day of employment (December 1, 2008).
- Verify if a successor for the President of North American Pharmaceuticals role has been named in subsequent filings.
- Review the 2007 Form 20-F for detailed risk factors referenced in this announcement.